CAJ | 학술논문

目的探讨急性早幼粒细胞自血病(APL)PML-RARα融合基因亚型及其临床关系.方法采用巢式反转录聚合酶链反应(RT-PCR)检测92例初诊APL患者PML-RARα融合基因不同转录本,根据结果分为长型(L型)和短型(S型)两组,比较两组间的临床特征、治疗反应及预后.结果 92例APL患者PML-RARα融合基因均为阳性,L型52例,占56.5%,S型40例,占43.5%;两组相比,患者性别、年龄、治疗前的白细胞计数、骨髓原始早幼粒细胞比例及染色体无明显差异;诱导治疗的完全缓解(CR)率、达CR的时间、维甲酸综合征(RAS)、弥漫性血管内凝血(DIC)、颅内出血的发生差异无统计学意义;两组缓解后总体生存率(OS)及无复发生存率(RFS)亦差异无统计学意义.结论 APL患者PML-RARα融合基因亚型与临床疗效、预后无关.
목적 탐토급성조유립세포자혈병(APL)PML-RARα융합기인아형급기림상관계.방법 채용소식반전록취합매련반응(RT-PCR)검측92례초진APL환자PML-RARα융합기인불동전록본,근거결과 분위장형(L형)화단형(S형)량조,비교량조간적림상특정、치료반응급예후.결과 92례APL환자PML-RARα융합기인균위양성,L형52례,점56.5%,S형40례,점43.5%;량조상비,환자성별、년령、치료전적백세포계수、골수원시조유립세포비례급염색체무명현차이;유도치료적완전완해(CR)솔、체CR적시간、유갑산종합정(RAS)、미만성혈관내응혈(DIC)、로내출혈적발생차이무통계학의의;량조완해후총체생존솔(OS)급무복발생존솔(RFS)역차이무통계학의의.결론 APL환자PML-RARα융합기인아형여림상료효、예후무관.
Objective To illustrate the clinical relevance of distinct PML-RARα fusion gene isoforms in acute promyelocytic leukemia (APL). Methods The nested reverse transcriptase polymerase chain reaction (RT-PCR) was used to detect the long (L) or short (S) PML-RARα fusion gene isoforms in 92 newly diagnosed APL so as to evaluate the clinical feature, therapeutic reaction and prognosis of the two fusion gene isoforms. Results PML-RARα fusion gene was positive in all 92 APL patients, of which 52(56.5 %) was L type and 40 (43.5 %) was S type. There were no significant differences between L type and S type in the aspect of sex, age, white blood cell count,the percentage of bone marrow blasts plus promyeloeytes and chromosome before treatment. And there were no significant differences between the two isoforms in complete remission (CR) rate, the time of getting CR as well as the occurrence of retinoic acid syndrome (RAS), disseminated intravascular coagulation (DIC), intraeranial hemorrhage. Also, there were no significant differences in overall survival rate (OS) and relapse-free survival rate (RFS) between the two isoforms. Conclusion PML-RARα fusion gene isoforms in APL were not correlated with clinical therapeutic effect or prognosis.